Triplaris peruviana

Triplaris peruviana: A Comprehensive Reference

1. Identity and Botanical Classification

Accepted scientific name: Triplaris peruviana Fisch. & C.A.Mey. (Fischer & Meyer ex C.A.Meyer). It is a species of eudicot in the family Polygonaceae (the buckwheat family). The species was formally described by Fischer and C.A. Meyer; a type specimen collected by Andrew Matthews in Peru in 1835 is held at the Royal Botanic Garden Edinburgh.

The species is recognized under the name Triplaris peruviana Fisch. & C.A.Mey. in Plants of the World Online (Kew Science). The genus Triplaris belongs to the subfamily Eriogonoideae and tribe Triplarideae within Polygonaceae. The genus includes 18 dioecious species of trees with a Neotropical distribution from southern Mexico to southern Brazil.

Common and regional names: Known commercially as a source of "Palo Santo," Triplaris peruviana is also called the "Ant Tree" due to its mutualistic association with ants; in Ecuador and Peru, Triplaris is known as Tangarana. The name "Palo Santo" translates to "Holy Wood." A close relative, Triplaris americana L., shares the local name palo santo and has been studied for chemical compounds including triterpenes (friedeline and friedelinol), flavonoids (quercetin and quercetin-3-O-α-L-arabinofuranoside), a phenylpropanoid glycoside (vanicoside), an amide (moupamide), and gallic acid. Some Bolivian ethnic groups apply closely related species to distinct therapeutic purposes, as discussed below.

Morphological and ecological description: It is an evergreen tree growing around 18 metres tall, with a straight, cylindrical bole that can be up to 50 cm in diameter and free of branches for up to 12–15 metres. The wood is sometimes harvested from the wild for local use, and hollow stems on the tree are inhabited by small, vicious ants which emerge quickly and attack anyone disturbing the tree. All species of the genus occur in lowland habitats from sea level to 2000 m in altitude and are considered important components in all stages of secondary succession.

Taxonomic context: Triplaris (Polygonaceae) comprises approximately 25 species distributed throughout South and Central America. The genus is monophyletic and all of the species are known to be myrmecophytes — that is, plants that harbor ants within their tissues as part of a mutualistic relationship.

2. Botanical Ecology: The Ant-Tree Mutualism

A defining ecological feature of Triplaris peruviana and its congeners is their intimate symbiosis with ants of the genus Pseudomyrmex. The ants colonize the hollow stems of their hosts, and in exchange, the plants benefit from a reduced degree of herbivory. Triplaris is mainly colonized by ants belonging to the large, New World-distributed genus Pseudomyrmex (approximately 200 species), which are characterized by possessing large eyes, aggressive behavior, and a painful sting.

The association between the myrmecophyte Triplaris and ants of Pseudomyrmex is an often-cited example of mutualism; one phylogenetic study reconstructed the interspecific relationships of Triplaris using five molecular markers (two chloroplast and three nuclear), and those of the associated Pseudomyrmex using two molecular regions (one mitochondrial and one nuclear). The pattern of distribution of both organisms reveals varying degrees of host specificity; most ants show broader host usage (promiscuous), but one species (P. dendroicus) is faithful to a single species of Triplaris. In most ant-plant interactions, host usage is not species-specific and preferences may result from geographical or ecological sorting.

This mutualistic biology is not merely of ecological interest; it is directly relevant to the tree's cultural identity and commercial harvest. The ants' defensive role helps protect the bark — the plant part most commonly harvested for medicinal and supplement use — from insect and vertebrate damage.

3. Geographic Distribution and Natural Source

Triplaris peruviana is native to Peru and is distributed within the broader Neotropical range of the genus. Most of the studies involving Triplaris were conducted by research groups located in Brazil, Peru, and Bolivia, probably because the genus has been used in folk medicine primarily in these countries. Triplaris peruviana belongs to the Polygonaceae (buckwheat) family and is native to Peru. The commercial supplement trade sources the bark from wild-harvested trees in the Peruvian Amazon and adjacent regions.

4. Common Forms and Preparations

In the contemporary dietary supplement market, T. peruviana is primarily encountered as a liquid hydroalcoholic bark extract (tincture). T. peruviana bark extract is sold under the name "Tangarana" and is prepared as a hydro-ethanol extract from Triplaris peruviana bark; the species is one of several referred to as "palo santo" (holy wood), and is wild-harvested using a specialized proprietary extraction process described as optimizing constituents in their original state to obtain broad-spectrum concentration.

Traditional preparations across Amazonian and Andean cultures have historically encompassed a wider variety of dosage forms, including decoctions (bark boiled in water), topical poultices of leaves or bark, and direct application of bark scrapings. Contemporary commercial presentation is almost exclusively as an alcohol-water tincture.

5. Traditional and Historical Use

5.1 Indigenous Amazonian and Andean Cultures

Triplaris peruviana, native to South America, has a history of traditional use among indigenous peoples, particularly in the Amazon basin. It has been used in folk medicine for the treatment of wounds and sores, often in the form of poultices or topical preparations made from its leaves or bark. Ethnobotanical surveys and traditional knowledge databases document the use of Triplaris species for their purported anti-inflammatory and antimicrobial properties, which may contribute to their role in wound healing.

Across the broader genus, the range of documented traditional applications is considerable. Some species have been used in folk medicine mainly to treat malaria, leishmaniasis, diarrhea, dysentery, pain, and inflammation. A more detailed ethnobotanical profile from the literature on the genus notes that in folk medicine, species of Triplaris are used in the treatment of malaria, diarrhea, dysentery, stomach pain, enteritis, fever, sores, inflammation of the throat, skin lesions induced by leishmaniasis, lymphadenitis, measles, cough, and intestinal worms, and it is also recorded as being used as an energetic stimulant and hallucinogen.

Triplaris pavonii Meisn., a related species, is used for the treatment of dysentery and burns by the Bolivian Kallawaya ethnic group. The Kallawaya are itinerant healers from the Bolivian Andes with a multi-century documented tradition of plant-based medicine.

5.2 Ceremonial and Spiritual Use

The name "Palo Santo" (Holy Wood) applied to T. peruviana in Peruvian and Ecuadorian contexts reflects a ceremonial dimension distinct from its strictly therapeutic applications. In Ecuador and Peru, Triplaris is known as Tangarana; "Palo Santo" translates to "Holy Wood" and refers to the use of the aromatic wood for traditional healing and in spiritual ceremonies in indigenous Latin American cultures for centuries. The "holy wood" is not only burned by the indigenous peoples of South and Central America in shamanic rituals but is also associated with antimicrobial properties; burning Palo Santo wood is described as a millennia-old tradition of indigenous peoples in Central and South America, and the balsamic-scented smoke was said to have a cleansing and harmonizing effect.

Note on "Palo Santo" nomenclature: It is important for researchers and consumers to recognize that the name "Palo Santo" is shared across multiple distinct species in Latin America — most prominently Bursera graveolens (Burseraceae), which is the source of the aromatic resinous wood widely burned as incense in South America. Triplaris peruviana is a separate species in a different botanical family. Published literature on the genus confirms this ambiguity: Triplaris peruviana is one of several species referred to as "palo santo" (holy wood). Chemical and pharmacological data attributed to "Palo Santo" may therefore not be applicable across species unless the botanical source is carefully confirmed.

5.3 Historical Introduction to Europe

Indigenous peoples attributed physical effects to the tree and used extracts of the fragrant wood against syphilis and other microbial infections. When the Spanish arrived in Peru in the 16th century, they brought the wood with them to Europe, where it was sold as a remedy during the syphilis epidemic. While this historical account reflects the cultural significance of these trees in early post-contact trade, it must be understood as narrative history rather than confirmed clinical evidence.

6. Key Chemical Constituents and Phytochemistry

6.1 Overview of the Genus

Phytochemical investigation of the Triplaris genus has been conducted primarily on T. americana and T. gardneriana, with considerably less published work on T. peruviana specifically. The genus Triplaris contains various classes of compounds, including phenolic acids, phenylpropanoids, monoterpenes, triterpenes, fatty acids, flavonoids, amides, phytosteroids, and aliphatic hydrocarbons. Flavonols were reported as the main phytochemical class of the genus, and the phytochemistry of the genus has been studied since 1974.

Flavonols represent the main class of secondary metabolites from Triplaris. Across the genus, phytochemical screening has revealed the presence of flavonoids, tannins, triterpenes, steroids, anthraquinones, anthrones, flavonoid glycosides, and coumarins, which could be responsible for the bioactivities shown by these plants.

6.2 Flavonoids

Flavonoids — and specifically flavonols — are the most thoroughly documented secondary metabolite class within the genus. The plants of the family Polygonaceae are known to produce a number of important secondary metabolites such as flavonoids; flavonols occur in 25% of the genera of the family, including Triplaris.

Two flavonoids — quercetin 3-O-α-L-arabinofuranoside and quercetin — were isolated from fresh fruits of T. americana; quercetin was also isolated and quantified by HPLC-DAD from the leaves of T. gardneriana. For T. gardneriana specifically, the ethyl acetate and chloroform fractions were subjected to column chromatography for isolation of quercetin and lupeol, respectively, with quantification using HPLC-DAD; the isolated phytochemicals were reported for the first time in the species, and the ethyl acetate fraction showed a higher content of quercetin at 9.967 ± 1.01 mg/g.

In T. cumingiana, three new flavonoid compounds were isolated from young leaves together with quercetin 3-O-α-L-(5"-O-galloyl)arabinofuranoside and quercetin 3-O-β-D-(6"-O-galloyl)glucopyranoside; compounds 1–5 were evaluated for cytotoxic activities against MCF-7, H-460, and SF-268 human cancer cell lines.

6.3 Triterpenes and Sterols

Studies on T. americana identified the chemical compounds present as triterpenes (friedeline and friedelinol), along with flavonoids, a phenylpropanoid glycoside (vanicoside), an amide (moupamide), and gallic acid. Lupeol — a pentacyclic triterpene — was also isolated from T. gardneriana leaves in the studies described above. Phytochemical studies on species of the genus Triplaris have identified triterpenes, an amide, phenylpropanoid glycoside, benzenoid, and flavonols both in simple and glycoside form.

6.4 Phenolic Acids and Phenylpropanoids

The phenolic compound profile of T. gardneriana seed ethanolic extract and fractions was examined by HPLC; twelve compounds were quantified and classified as either phenolic acids or flavonoids. Gallic acid, a hydroxybenzoic acid, was identified in T. americana, and vanicoside (a phenylpropanoid glycoside) has been documented in the same species.

6.5 Anthraquinones and Other Metabolites

Phytochemical screening of Triplaris species, particularly those in the broader Polygonaceae family context, has identified anthraquinones and anthrones in addition to the flavonoid, tannin, triterpene, steroid, flavonoid glycoside, and coumarin classes. However, it should be noted that the most detailed phytochemical characterization in peer-reviewed literature has been conducted on T. americana and T. gardneriana, with peer-reviewed data on isolates from T. peruviana specifically being very limited in the published literature as of the search date.

7. Mechanisms of Action

Mechanistic research on Triplaris is almost entirely preclinical and is extrapolated from work on the better-studied congeners, primarily T. gardneriana. No mechanism-of-action studies specific to T. peruviana isolates were identified in the peer-reviewed literature. The following mechanisms are attributed to secondary metabolites found across the genus:

7.1 Antioxidant Activity

The antioxidant capacity of T. gardneriana seed ethanolic extract has been assessed, with bioaccessibility and bioavailability of phenolic compounds examined in biological systems. Twelve phenolic compounds were quantified by HPLC; the DPPH assay revealed samples with concentration-dependent radical scavenging activity, with the methanolic fraction showing the largest activity (SC50 11.45 ± 0.02 μg/mL). This work was conducted in vitro.

7.2 Anti-inflammatory Mechanisms

For T. gardneriana, one study demonstrated for the first time that the anti-inflammatory effect of seeds occurs due to a modulatory effect on human neutrophil degranulation and free-radical scavenging activity. The study methodology involved evaluation of anti-inflammatory properties through multiple in vitro approaches, including a protein anti-denaturation test, scavenging of reactive oxygen species (ROS), and myeloperoxidase (MPO) inhibition in human neutrophils. These are in vitro cell-based findings and have not been confirmed in human clinical trials.

7.3 Antimalarial / Antiplasmodial Mechanisms

For T. americana — the most pharmacologically studied congener — its application for the treatment of malaria in Peru is supported by the detected high in vivo activity of the ethanol extract of the bark against Plasmodium vinckei petteri, as well as its in vitro activity against Plasmodium falciparum. A study screening plants used by Mosetene indigenous people in Bolivia found that forty-six different species were screened for antimalarial properties; thirty-three extracts were tested against Plasmodium falciparum chloroquine-resistant strain (Indo) in vitro and forty-seven were evaluated in vivo on the rodent malaria P. vinckei petteri 279BY. Among the in vivo most active extracts were Triplaris americana bark — though this plant was not specifically used for antimalarial purposes by the Mosetene.

8. Scientific Evidence by Area of Use

Critical caveat: In terms of pharmacological investigations, T. americana and T. gardneriana are considered the most studied species. Scientific studies specifically investigating the wound-healing efficacy or bioactive compounds of Triplaris peruviana are extremely limited or nonexistent. While some related species in the Triplaris genus have been noted for containing secondary metabolites with potential biological activities, direct pharmacological evidence — such as clinical or in vivo studies — supporting the wound-healing claims of T. peruviana remains lacking. Thus, the use of T. peruviana for wounds and sores is justified primarily by tradition, with minimal scientific substantiation to date. The systematic review by ScienceDirect (2021) reached a similar conclusion for the genus as a whole: studies developed with Triplaris species are still limited; the review shows that little pre-clinical or in vivo research is available to prove the ethnopharmacological records in the genus, and further studies are encouraged.

8.1 Antimicrobial Activity

Evidence level: In vitro only, genus-level data; no human studies.

Plants of the Triplaris genus have shown activities including antioxidant, cytotoxicity against human cancer cell lines, anticholinesterase, anti-HIV, larvicidal, antimicrobial, leishmanicidal, immunomodulatory, agglutinating, antiplasmodial, antimalarial, anti-inflammatory, stimulating smooth muscle, and molluscicidal activity. However, these activities were demonstrated across multiple species and study types, not all specifically in T. peruviana.

For antimicrobial activity specifically in the genus, the antimicrobial, antioxidant, and anticholinesterase activities of ethanolic seed extracts of twenty-one plant species from the Brazilian semiarid region were investigated, with extracts tested against six bacterial strains and three yeasts; six extracts showed activity against Salmonella choleraesuis, Staphylococcus aureus, and Bacillus subtilis. The Triplaris gardneriana extract showed activity against three species, with MIC values of 18.8, 13.76, and 11.15 mg/mL, respectively. These MIC values are substantially higher than those for conventional antibiotics, suggesting modest in vitro potency at best.

For T. gardneriana leaves specifically, samples showed good antibacterial activity; quercetin was isolated and quantified, making the species a potential alternative source of this secondary metabolite. No analogous isolate-level antibacterial studies for T. peruviana bark were identified in the peer-reviewed literature.

8.2 Anti-inflammatory Activity

Evidence level: In vitro only, genus-level data; no human studies.

Triplaris gardneriana (Polygonaceae family) is a plant species from the Brazilian semiarid region used in local traditional medicine for the treatment of inflammatory conditions such as hemorrhoids. The in vitro anti-inflammatory mechanism was demonstrated via modulatory effect on human neutrophil degranulation and free-radical scavenging activity, as described above. No randomized controlled trials, cohort studies, or any other human clinical evidence for anti-inflammatory effects of T. peruviana or any Triplaris species was identified in the published literature.

8.3 Antimalarial and Antiprotozoal Activity

Evidence level: In vitro and rodent in vivo data for closely related species; no human clinical trials.

The antimalarial evidence base for Triplaris rests primarily on two types of studies: (1) in vitro screens against Plasmodium falciparum, and (2) in vivo rodent models using Plasmodium vinckei petteri. As described above, Triplaris americana bark was among the in vivo most active extracts in a 46-species Bolivian screen, though it was not a plant traditionally used for malaria by the study's focal indigenous group. Extracts from eight plant species of Peruvian Amazonia currently used in traditional Peruvian medicine, mostly as antileishmanial remedies and also as painkiller, antiseptic, antipyretic, anti-inflammatory, antiflu, astringent, diuretic, antipoison, anticancerous, antiparasitic, insecticidal, or healing agents, have been tested for their antileishmanial, antitrypanosomal, and cytotoxic activity. No published clinical trials involving Triplaris species for malaria, leishmaniasis, or any tropical disease in human subjects were identified.

8.4 Antioxidant Activity

Evidence level: In vitro only; no human studies.

As detailed in section 7.1, in vitro antioxidant activity via DPPH and related assays has been demonstrated for T. gardneriana seed extracts. Extracts from bark of T. americana showed antioxidant activity in a quenching of luminol-enhanced chemiluminescence assay. No clinical data exist on the systemic antioxidant effects of any Triplaris preparation in humans.

8.5 Cytotoxic and Antiproliferative Activity

Evidence level: In vitro only; no human studies.

Cytotoxic flavonol glycosides were isolated from T. cumingiana, another species in the genus. Compounds 1–5 isolated from T. cumingiana were evaluated for cytotoxic activities against the MCF-7, H-460, and SF-268 human cancer cell lines. Toxicological evaluation for T. gardneriana found that toxicological tests included hemolytic activity, toxicity toward the brine shrimp Artemia, cytotoxicity against breast cancer cells (MCF7), and acute oral toxicity in rodents; in addition, toxicogenomics techniques were used to determine genome expression in MCF7 cells exposed to the ethanolic extract. The results showed that the extract exhibits approximately 60% hemolytic activity at the highest tested concentration (64 µg/mL). This hemolytic finding is a safety-relevant observation (see Section 10).

9. Body Systems and Health Areas Associated with Triplaris peruviana

Based on documented traditional uses and preclinical data across the genus, the following body systems and health areas are associated with T. peruviana and related Triplaris species, though emphasis must be placed on the absence of human clinical evidence:

• Immune and infectious disease: Traditional use against malaria, leishmaniasis, syphilis, and gonorrhea; supported only by in vitro and rodent data for congeners.
• Gastrointestinal system: Traditional use for diarrhea, dysentery, stomach pain, enteritis, ulcers, gastritis, and heartburn, documented ethnobotanically across the genus.
• Skin and wound healing: Topical traditional use for wounds, sores, skin lesions from leishmaniasis, and burns; no clinical evidence for efficacy.
• Inflammatory conditions: Traditional use for pain, inflammation, and hemorrhoids; in vitro neutrophil and antioxidant data from T. gardneriana.
• Respiratory system: Traditional use for cough, bronchitis, and flu-like illness, documented in ethnobotanical surveys of the genus.
• Reproductive and urological: Traditional use against venereal diseases including syphilis and gonorrhea; historical documentation only.

10. Dosage Forms and Reported Dosages

No peer-reviewed clinical trials have established a therapeutic dosage for T. peruviana preparations. The dosage figures below are drawn exclusively from commercially reported product information and are not substantiated by clinical evidence:

• One commercially available tincture states that each 1.5 mL (30 drops) recommended daily dosage contains 1.5 mL Palo Santo alcohol-water extract equivalent to 500 mg Palo Santo bark. Ingredients are listed as pure cane alcohol, osmotic water, and Palo Santo (Triplaris peruviana) bark from Peru.
• The suggested adult use (age 16+) is 15–30 drops, two times daily in 120 mL (4 oz.) of water. It is recommended to start with a lower dose of 1 drop, titrating up to 30 drops, with a maximum of 60 drops per day.

No standardized extract specifications (e.g., minimum flavonol content, quercetin quantification) are publicly reported for T. peruviana commercial preparations in the peer-reviewed literature. No pharmacokinetic data (absorption, distribution, metabolism, or excretion) are available for T. peruviana extracts in humans.

11. Safety Considerations

Absence of clinical safety data: The use of Triplaris peruviana for wounds and sores — as one example of its applications — is justified primarily by tradition, with minimal scientific substantiation to date, and further research would be needed to validate its efficacy and safety.

Hemolytic potential: A toxicological study of the closely related T. gardneriana found that the ethanolic extract demonstrated approximately 60% hemolytic activity at the highest tested concentration (64 µg/mL) in vitro. This is a preclinical finding indicating potential red blood cell membrane disruption at high concentrations; its relevance to oral supplemental doses in humans is unknown, but it underscores the need for clinical safety evaluation.

Species identification and nomenclature hazards: As noted in Section 5.2, the name "Palo Santo" is applied to multiple unrelated species. Consumers and researchers must verify the botanical source to avoid confusion with Bursera graveolens or other "palo santo" species with different chemical profiles and safety data.

No interaction data: No peer-reviewed studies examining drug-herb interactions, effects in pregnancy or lactation, or contraindications specific to T. peruviana preparations were identified. The general pharmacological profile of the genus — including demonstrated in vitro effects on smooth muscle, antiplasmodial and cytotoxic activity — suggests that interactions with anticoagulants, antiparasitic drugs, and immune-modulating agents cannot be excluded but have not been formally studied.

Regulatory status: T. peruviana bark extracts are sold as dietary supplements in the United States and as food supplements in the European Union. Neither the U.S. FDA, the NIH Office of Dietary Supplements, the European Medicines Agency (EMA), nor the WHO has issued a formal monograph, safety opinion, or regulatory guidance specifically for T. peruviana.

12. Summary of Evidence Quality

All findings indicate that Triplaris is an important genus of the Polygonaceae family; however, considering its chemical and pharmacological importance, the studies developed with Triplaris species are still limited, representing an opportunity to investigate new bioactive molecules and extracts. For T. peruviana specifically, the body of published peer-reviewed pharmacological and clinical evidence is extremely sparse. The vast majority of mechanistic and biological activity data derives from work on T. americana and T. gardneriana, neither of which is identical to T. peruviana. No human clinical trials — randomized controlled, observational, or otherwise — for any indication have been conducted with T. peruviana preparations. All health-related claims rest on traditional use and genus-level in vitro or rodent preclinical data, which must be considered preliminary and of low evidentiary quality for human health applications.

References

• NCBI Taxonomy: Triplaris peruviana
• Plants of the World Online: Triplaris peruviana Fisch. & C.A.Mey. (Kew Science)
• JSTOR Global Plants: Type specimen of Triplaris peruviana (Royal Botanic Garden Edinburgh)
• Genus Triplaris (Polygonaceae): A review on traditional medicinal use, phytochemistry and biological activities. Journal of Ethnopharmacology, 2021 (ScienceDirect)
• Genus Triplaris (Polygonaceae): A review on traditional medicinal use, phytochemistry and biological activities (PubMed abstract)
• Genus Triplaris (Polygonaceae): A review on traditional medicinal use, phytochemistry and biological activities (ResearchGate)
• Chemical constituents from Triplaris americana L. (Polygonaceae) (ResearchGate)
• Chemical constituents from Triplaris americana L. (Polygonaceae) — ADS/Biosystems abstract
• Triplaris gardneriana seeds extract exhibits in vitro anti-inflammatory properties in human neutrophils after oxidative treatment (PubMed)
• Phenolic compounds of Triplaris gardneriana can protect cells against oxidative stress (PubMed)
• Evaluation of seeds ethanolic extracts of Triplaris gardneriana Wedd. using in vitro and in vivo toxicological methods (PubMed)
• Phytochemical identification and quantification of quercetin in Triplaris gardneriana Wedd. leaves by HPLC-DAD with evaluation of antibacterial activity. Natural Product Research (Taylor & Francis)
• Cytotoxic Flavonol Glycosides from Triplaris cumingiana (ResearchGate)
• The search for natural bioactive compounds through a multidisciplinary approach in Bolivia. Part II. Antimalarial activity of some plants used by Mosetene indians (PubMed)
• Fidelity and Promiscuity in an Ant-Plant Mutualism: A Case Study of Triplaris and Pseudomyrmex (PMC/PLOS ONE)
• Fidelity and Promiscuity in an Ant-Plant Mutualism: A Case Study of Triplaris and Pseudomyrmex (PLOS ONE)
• Neotropical ant-plant Triplaris americana attracts Pseudomyrmex mordax ant queens during seedling stages (PMC)
• Triplaris peruviana — Useful Tropical Plants Database (Ken Fern)
• Relationship: Wounds and Sores and Triplaris peruviana — Caring Sunshine
• Antileishmanial, antitrypanosomal, and cytotoxic screening of ethnopharmacologically selected Peruvian plants. Parasitology Research (Springer)
• GC-MS analysis of esterified fatty acids obtained from leaves and seeds of Triplaris gardneriana Wedd. (ResearchGate)